Do you want to read an article? Please log in or register.
Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO
Lung, Respiratory and Thoracic Cancer
Related content
ELCC 2026
Lung, Respiratory and Thoracic Cancer
IMpower133/IMbrella A: Long-term survival and molecular subtype analyses with first-line atezolizumab in extensive-stage SCLC
Lung, Respiratory and Thoracic Cancer
Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes
Lung Cancer
Krayim B, Shalata W, Bar J, Moskovitz M, Rotem O, Urban D, Sorotsky HG, Kian W, Hanovich E, Marie R, Mann S, Gillis R, Basel A, Kornev G, Asna N, Peled N, Roisman LC
doi: 10.1016/j.lungcan.2025.108598
Lung, Respiratory and Thoracic Cancer
Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis
Lung Cancer
Tang Y, Du W, Zhang X, Yang X, Zhou Y, Fu S, Zhang L, Hong S
doi: 10.1016/j.lungcan.2025.108855
WCLC 2025
Lung, Respiratory and Thoracic Cancer
CheckMate 816: Neoadjuvant nivolumab plus chemotherapy provides long-term OS benefit in patients with early-stage NSCLC
Lung, Respiratory and Thoracic Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Kinehara Y, Matsumoto K, Shiroyama T, Komuta K, Tamiya M, Nishino K, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A
doi: 10.1016/j.lungcan.2026.109336
Gastrointestinal Cancer
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Eur J Cancer
Lee PC, Cortellini A, Stefanini B, Yoo C, Chon HJ, Cheon J, Kudo M, Nishida N, Scheiner B, Pinter M, Lombardi P, Fulgenzi CAM, D'Alessio A, Brunetti L, Torkpour A, Valenzi E, Crowley F, Marron TU, Hsu WF, Celsa C, Cabibbo G, Cammà C, Galle PR, Vivaldi C, Masi G, Sharma R, Lin RP, Lin CY, Wietharn B, Saeed A, Tovoli F, Piscaglia F, Dalbeni A, Auriemma A, Sacerdoti D, Parisi A, Manfredi GF, Dondo A, Rimassa L, Pirisi M, Schönlein M, von Felden J, Singal AG, Parkih ND, Andanamala H, Ulahannan S, Roehlen N, Thimme R, Huang YH, Pinato DJ
doi: 10.1016/j.ejca.2026.116749
Gastrointestinal Cancer
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population
Semin Oncol
Vitiello F, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Scartozzi M, Tamburini E, Foschi FG, Persano M, Rossari F, Foti S, Camera S, De Cobelli F, Aldrighetti L, Cascinu S, Casadei-Gardini A, Rimini M
doi: 10.1016/j.seminoncol.2025.152348
Gastrointestinal Cancer
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data
Clin Cancer Res
Campani C, Shim JH, Bouattour M, Touchefeu Y, Delhoume V, Rosmorduc O, Pascale A, An J, Lee HC, Regnault H, Thabut D, Amaddeo G, Ningarhari M, Ollivier-Hourmand I, Métivier C, Ronot M, Ntandaja-Wandji L, Ozenne V, Sidali S, Marra F, Hollande C, Ganne-Carrié N, Nahon P, Peron JM, Lequoy M, Sharma R, Liver Cancer Group P, Allaire M, Nault JC
doi: 10.1158/1078-0432.CCR-25-4943